Retinopathy of Prematurity (ROP)

1. Clinical Overview

Summary

Retinopathy of Prematurity (ROP) is a potentially blinding vasoproliferative eye disorder affecting premature infants of low gestational age and birth weight. It is characterized by the disruption of normal retinal angiogenesis, leading to the proliferation of abnormal, fragile blood vessels (neovascularization) at the junction of the vascularized and avascular retina. While the majority of ROP cases regress spontaneously with no visual sequelae, a minority progress to severe staging involving fibrous scar formation, retinal traction, and total retinal detachment. [1,2]

Key Facts

• Definition: A disorder of retinal vessel development in preterm infants caused by the interplay of hyperoxia, hypoxia, and growth factors (VEGF/IGF-1).
• Prevalence: ROP affects approximately 60% of infants less than 1500g birth weight, but thresholds for "severe" ROP requiring treatment (Type 1) are met in only ~6-10%. [3]
• Historical Context: Originally termed "Retrolental Fibroplasia" in the 1940s, it caused an epidemic of blindness before the link to unmonitored incubator oxygen was discovered.
• Key Management: Strict oxygen saturation targets (91-95%) prevent the disease. [4] Treatment involves Laser Photocoagulation (Gold Standard) or Intravitreal Anti-VEGF agents. [5,6]
• Critical Threshold: "Type 1 ROP" acts as the universal trigger for intervention within 48-72 hours. [7]
• Key investigation: Binocular Indirect Ophthalmoscopy (BIO) with scleral indentation or wide-field retinal imaging (RetCam).

Clinical Pearls

The "Oxygen Paradox": Oxygen is a double-edged sword. In the first weeks of life (Phase 1), high oxygen stops vessels growing (Vaso-obliteration). In the later weeks (Phase 2), the retina grows but has no vessels, causing it to scream for oxygen, triggering frank neovascularization. Stability is key—"sats of 100% are toxic to the eye". [4,8]

The "Crunch" Phenomenon: When treating severe fibrotic ROP with Anti-VEGF injections, the vessels may regress too rapidly, causing the scar tissue to contract violently. This can crunch the retina and cause a tractional detachment days after treatment.

Plus Disease is King: While the "Stage" describes the anatomy of the ridge, "Plus Disease" describes the activity of the disease engine. Tortuous arteries and dilated veins at the optic nerve mean the eye is pumping out massive amounts of VEGF. No Plus usually means you can wait; Plus means you must act. [9]

Why This Matters Clinically

ROP is a preventable cause of childhood blindness. The "Third Epidemic" of ROP is currently occurring in middle-income countries (India, China, Latin America) where survival of extremely preterm infants is increasing, but resources for meticulous oxygen blending and monitoring are sometimes lacking. [10,11] A missed screening examination is a medico-legal catastrophe and a tragedy for the child.

---

2. Epidemiology

Incidence & Prevalence

• Incidence by Gestation:
  • 24-25 weeks: > 90% develop some degree of ROP. [3]
  • 28-30 weeks: 40-50% incidence.

  • 32 weeks: Rare (less than 1%) in developed nations with good oxygen control.

• Treatment Rate: Only ~6-10% of screened infants reach threshold for treatment (Type 1 ROP). [3,7]
• Blindness: Worldwide, ROP accounts for 6-18% of childhood blindness, varying heavily by region (up to 40% in some Eastern European and Latin American cohorts). [10]

Demographics and Geography

Risk Factors

The Primary Triad:

1. Prematurity: Incomplete vasculogenesis (Retina is largely avascular at birth).
2. Hyperoxia: Unmonitored oxygen supplementation suppresses VEGF. [4,8]
3. Poor Postnatal Growth: Low IGF-1 levels (poor weight gain) predict severe ROP. [12] This is the basis of the WINROP screening algorithm.

Secondary Factors:

• Sepsis: Systemic inflammation upregulates cytokines. [13]
• Blood Transfusions: Adult haemoglobin (HbA) releases oxygen to tissues more readily than Fetal haemoglobin (HbF), potentially causing retinal hyperoxia even with normal saturations. [14]
• Intraventricular Haemorrhage (IVH): Correlates with general instability.
• Necrotizing Enterocolitis (NEC): Surgery and inflammation increase risk. [13]
• Maternal Factors: Pre-eclampsia, maternal smoking, multiple gestation.

Risk Factor Stratification

---

3. Pathophysiology

Normal Retinal Vascular Development

• Vessels originate from the optic disc at 16 weeks gestation.
• They grow centrifugally (outwards). [1]
• Reach the nasal ora serrata by 36 weeks.
• Reach the temporal ora serrata by 40 weeks (term).
• Implication: The temporal retina is the last to vascularize and the most common site for ROP.

Molecular Pathophysiology: The VEGF-IGF-1 Axis

VEGF (Vascular Endothelial Growth Factor):

• Primary angiogenic driver in the developing retina. [8]
• Produced by hypoxic retinal cells (especially photoreceptors and Müller cells).
• Binds to VEGFR-2 receptors on endothelial cells, promoting proliferation, migration, and tube formation.
• Oxygen-sensitive: Hyperoxia suppresses VEGF production via HIF-1α (Hypoxia-Inducible Factor 1-alpha) degradation. [8]

IGF-1 (Insulin-like Growth Factor 1):

• Essential permissive factor for VEGF-driven angiogenesis. [12]
• Levels are LOW in preterm infants (normally supplied transplacentally in third trimester).
• Poor postnatal nutrition = persistently low IGF-1.
• Critical Concept: VEGF alone is insufficient for normal vessel growth; IGF-1 is required for endothelial survival and vessel maturation. [12]
• Low IGF-1 in Phase 1 = arrested vessel growth.
• Return of IGF-1 in Phase 2 + high VEGF (from hypoxic retina) = pathological neovascularization.

HIF-1α (Hypoxia-Inducible Factor 1-alpha):

• Master regulator of cellular hypoxia response.
• Normoxia/Hyperoxia: HIF-1α is hydroxylated by prolyl hydroxylases (PHDs) and degraded via von Hippel-Lindau (VHL) ubiquitin pathway.
• Hypoxia: PHDs are inactive, HIF-1α accumulates, translocates to nucleus, and upregulates VEGF gene expression. [8]

The Biphasic Theory of ROP

Phase 1: Vaso-Obliteration (The Hyperoxic Phase)

• Timing: Birth to ~30-32 weeks PMA.
• Environment: The fetus moves from the hypoxic womb (PaO2 ~30mmHg) to the relative hyperoxia of room air (PaO2 60-100mmHg) + supplemental O2. [4,8]
• Molecular Mechanism:
  • High tissue oxygen → HIF-1α degradation → VEGF suppression.
  • Low IGF-1 (preterm infant) → lack of endothelial survival signals.
  • Existing fragile capillaries undergo apoptosis and obliterate.
• Result: Normal vessel growth stops. The peripheral retina remains avascular (arrested vasculogenesis).

Phase 2: Vaso-Proliferation (The Hypoxic Phase)

• Timing: ~32-34 weeks onwards (as retina matures metabolically).
• Environment: The neural retina continues to grow and becomes metabolically active (photoreceptors mature, oxygen demand increases).
• Molecular Mechanism:
  • Avascular retina cannot meet metabolic demand → tissue hypoxia.
  • Hypoxia → HIF-1α stabilization → massive VEGF upregulation.
  • IGF-1 levels rise with postnatal growth and nutrition.
  • High VEGF + IGF-1 = unregulated angiogenesis. [8,12]
• Pathological Result:
  • Neovascularization: New vessels sprout at the vascular-avascular junction.
  • These vessels are leaky (poor pericyte coverage), fragile, and disorderly.
  • Instead of growing flat along the retina, they grow perpendicular into the vitreous gel (extraretinal fibrovascular proliferation).
  • Vessels bleed → vitreous hemorrhage.
  • Myofibroblasts form scaffolds (scar tissue). [1,8]

Phase 3: Cicatrization (Scarring and Fibrosis)

• The fibrovascular tissue undergoes contraction (myofibroblast-mediated).
• This exerts traction on the retina, pulling it away from the Retinal Pigment Epithelium (RPE).
• Result: Tractional Retinal Detachment (Stage 4-5). [1]

The Role of Inflammation

• Inflammatory cytokines (IL-6, IL-8, TNF-α) are elevated in infants who develop severe ROP. [13]
• Sepsis, NEC, and IVH all contribute to systemic inflammatory milieu.
• Inflammation may amplify VEGF signaling and endothelial dysfunction.

---

4. Classification (ICROP 3)

The International Classification of Retinopathy of Prematurity (3rd Edition, 2021) standardizes ROP description. [9]

1. Location (Zones)

Defined relative to the Optic Disc:

• Zone I: A circle centered on the optic disc, with a radius twice the distance from the disc to the fovea (macula). Highest Risk.
• Zone II: A donut shape surrounding Zone I, extending to the nasal ora serrata (edge of retina). Moderate Risk.
• Zone III: The remaining temporal crescent of retina. Lowest Risk.
• Posterior Zone II: A new term in ICROP3 describing the area of Zone II adjacent to Zone I. Behaves aggressively. [9]

2. Severity (Stages)

Describes the appearance of the junction between vascular (central) and avascular (peripheral) retina:

• Stage 1: Demarcation Line. A thin, flat, white line separating vascular from avascular retina.
• Stage 2: Ridge. The line thickens and rises up from the plane of the retina (like a speed bump). Color is pink/white.
• Stage 3: Extraretinal Fibrovascular Proliferation. Neovascular vessels grow off the ridge into the vitreous jelly. Appearance is red/ragged.
• Stage 4: Partial Retinal Detachment.
  • 4A: Fovea spared (Good visual potential if treated).
  • 4B: Fovea detached (Poor prognosis).
• Stage 5: Total Retinal Detachment. Funnel configuration. "White pupil" (Leukocoria). [1,9]

3. Activity (Plus Disease)

• Plus (+): Dilatation and tortuosity of posterior pole arterioles and venules in at least 2 quadrants. [9] This indicates high VEGF activity and is the hallmark of severe, active disease.
• Pre-Plus: Abnormal vascular dilation/tortuosity insufficient for "Plus" but more than normal. (Borderline category).
• No Plus: Normal caliber vessels.

Clinical Significance: Plus disease is a MORE important predictor of progression than Stage alone. [7,9]

Plus Disease: The Critical Diagnostic Challenge [36,37,46]

Plus disease is the SINGLE MOST IMPORTANT predictor of ROP progression and treatment need, yet it is the MOST SUBJECTIVE element with highest inter-examiner disagreement. [36]

The Standard Photograph Problem:

• ICROP defines Plus using a "standard photograph" showing representative vessel tortuosity/dilation [9]
• Problem: Inter-observer agreement is only 50-70% (experts disagree half the time!) [36]
• "Pre-Plus" has even worse reliability (40-60% agreement) [36]

Why Is Plus Disease So Hard to Diagnose? [37,46]

1. Continuous spectrum: Plus is not binary (present/absent) but exists on a continuum
2. Vascular variability: Normal vessel caliber varies by postmenstrual age, race, and individual anatomy
3. Quadrant variations: Vessels may be tortuous in some quadrants but not others
4. Temporal evolution: Plus can develop over 3-7 days, creating "borderline" appearances
5. Photographic distortion: RetCam images have different magnification than indirect ophthalmoscopy

Quantitative Approaches to Reduce Subjectivity: [37,46]

Clinical Approach to Borderline Plus/Pre-Plus: [9,46]

1. Document uncertainty: Write "Pre-Plus" or "vascular abnormalities not meeting Plus threshold"
2. Short-interval follow-up: Re-examine in 3-5 days (not 1 week)
3. Serial imaging: Compare current RetCam image to previous exam (progression suggests real Plus)
4. Err toward treating: If genuinely uncertain between Pre-Plus and Plus in Zone I → treat (overtreatment safer than undertreatment in posterior disease)
5. Get second opinion: Have colleague examine or send images to tertiary center

Plus Disease and Treatment Urgency: [7,9,43]

• Plus disease = "VEGF storm" → Treat within 48 hours [7]
• Severe Plus ("++ Plus") in Zone I = A-ROP → Treat within 24 hours [43]
• No Plus = Can observe closely (even if Stage 3) → Weekly exams

4. Aggressive ROP (A-ROP)

• Formerly "Aggressive Posterior ROP" (AP-ROP). [9]
• Rapidly progressive disease in Zone I or Posterior Zone II.
• Features: Severe Plus disease, intra-retinal shunting, flat neovascularization (no obvious ridge).
• Danger: Can progress to detachment in days without passing through classic stages 1-3. [9]
• Management: Urgent treatment required (within 48 hours).

ICROP3 vs ICROP2 (2005) Differences

Key updates in the 2021 classification: [9]

ICROP3 Innovations and Clinical Impact (2021) [9]

The 2021 ICROP3 revision represents the most significant update since 2005, driven by:

1. Anti-VEGF Era Considerations:

• Recognition that anti-VEGF treated eyes have unique regression patterns (peripheral vessels continue to grow normally, unlike laser-treated eyes with permanent avascular zones). [32]
• New terminology for "reactivation" (ROP recurrence after initial regression) vs. "recurrence" (new disease after complete regression). [9]
• Emphasis on prolonged surveillance until full vascularization (not just regression of acute ROP). [21,32]

2. Imaging Technology Integration:

• Acknowledges wide-field digital imaging (RetCam, Optos) as complementary to binocular indirect ophthalmoscopy. [16,33]
• Standardized image capture protocols for telemedicine screening. [33]
• AI-assisted Plus disease detection algorithms (i-ROP DL, RIDROP) showing 91-94% accuracy. [31,34]

3. Global Disease Variations:

• Recognition of geographic differences in ROP patterns (Third Epidemic in middle-income countries). [10,11]
• Acknowledgment that "aggressive ROP" can occur in Zone II (not just posterior pole). [9]
• Flexible screening criteria for resource-limited settings. [35]

4. Posterior Zone II Definition:

• Defined as the annular area of Zone II adjacent to Zone I (essentially the "inner half" of Zone II). [9]
• Clinical significance: Disease in posterior Zone II behaves more like Zone I (rapid progression, higher risk). [9]
• Treatment threshold: Some experts advocate treating posterior Zone II Plus disease as aggressively as Zone I. [9]

5. Plus Disease Spectrum Concept:

• ICROP3 acknowledges Plus disease exists on a continuum (mild → moderate → severe). [9]
• "Pre-Plus" retained but acknowledged as having high inter-observer variability (50-70% disagreement). [36]
• Development of quantitative vascular metrics (tortuosity index, vessel diameter ratio) to reduce subjectivity. [37]
• Clinical Pearl: When in doubt between Pre-Plus and Plus, repeat exam in 3-5 days rather than waiting 1 week. [9]

---

5. Clinical Examination & Screening

Screening Strategy

UK (Royal College of Ophthalmologists) Criteria: [15]

• Inclusion: less than 1251g OR less than 31+0 weeks GA.
• Timing: First screen at 4 weeks postnatal age or 31 weeks PMA (whichever is later).

USA (AAP) Criteria: [3]

• Inclusion: ≤ 1500g OR ≤ 30 weeks GA.
• Timing: First screen at 4-6 weeks postnatal age (or 31 weeks PMA).

Rationale: Screening before 31 weeks PMA is not useful because the retina is too immature to develop treatment-requiring ROP, and pupil dilation is difficult. [3,15]

International Screening Variation [35,41]

Different countries use different thresholds based on local ROP epidemiology:

Key Principle: Middle-income countries need BROADER screening criteria because ROP develops in larger, more mature infants due to unmonitored oxygen. [10,11,35,41]

Screening Cessation Criteria [3,15,42]

When can we safely STOP screening?

UK/USA Consensus: [3,15]

1. Full vascularization to ora serrata in both eyes (Zone III with vessels reaching periphery)
2. Postmenstrual age ≥45 weeks AND no prethreshold disease (regressed ROP stable for ≥2 weeks)
3. Complete regression of ROP (all active disease resolved, vessels matured normally)

NEVER stop screening if: [42]

• Anti-VEGF treatment performed (continue until full vascularization, often 55-65 weeks PMA) [21,32]
• Persistent avascular retina (risk of late reactivation)
• Zone I disease history (higher reactivation risk even after regression)

Premature Discharge Pitfall: [42]

• Historically, ~5% of ROP blindness occurred because screening stopped at 42-45 weeks PMA before full vascularization
• With anti-VEGF era, late reactivation at 55-70 weeks PMA is well-documented [21,32]
• Medicolegal emphasis: Document specific cessation criteria met before discharge from ROP service

NICU Oxygen Management: Practical Strategies [4,17,47]

SpO2 Alarm Settings for Preterm Infants less than 32 weeks:

Avoiding Oxygen Variability (Independent ROP Risk Factor): [18,47]

• Problem: Frequent swings between hypoxia/hyperoxia may be MORE harmful than sustained mild hyperoxia
• Mechanism: Repeated ischemia-reperfusion → oxidative stress → retinal vascular damage [47]
• Evidence: Coefficient of variation in SpO2 \u003e 8% associated with 2.5x increased risk of severe ROP [18,47]
• Solutions:
  • "Manual FiO2 adjustments: gradual increments (1-2%) with 5-minute intervals"
  • "Automated oxygen control (servo-controllers): reduce variability by 30-40% [47]"
  • "Continuous SpO2 histogram monitoring: identify infants with high variability"

NICU Nursing Protocol Example: [47]

1. Measure SpO2 variability: Document highest/lowest SpO2 each hour on ventilator/CPAP
2. Flag high-risk infants: \u003e 10 SpO2 alarms per hour = increased ROP risk
3. Optimize respiratory support: Consider CPAP upgrade to SIMV if frequent desaturations
4. Daily oxygen audit: Review FiO2 charting to identify periods of unintended hyperoxia (\u003e 95% SpO2 for \u003e 1 hour)

Examination Technique

Preparation:

1. Dilation: Cyclopentolate 0.5% + Phenylephrine 2.5% drops administered 1 hour prior. (Tropicamide sometimes used).
2. Timing: Ideally 30-60 minutes after feeding (stable vital signs).

Procedure:

1. Infant swaddled (containment holding) ± oral sucrose for analgesia.
2. Local anaesthetic drops (Proxymetacaine 0.5%).
3. Insert speculum (Alfonso or Sauer wire speculum).
4. Binocular Indirect Ophthalmoscopy (BIO) with 28D or 30D lens.
5. Scleral indentation: Use a depressor to rotate the eye and view the periphery (Ora Serrata).
6. Documentation: Digital imaging (RetCam, RetCam3, or wide-field fundus camera) is increasingly the standard for medico-legal record and telemedicine (e-ROP). [16]

Safety Considerations:

• Bradycardia and oxygen desaturation can occur during examination (vagal response).
• Continuous cardiorespiratory monitoring is mandatory.
• Senior neonatal staff should be present or immediately available.

Advanced Imaging Modalities: [16,33,48]

Fluorescein Angiography in ROP (Research Tool): [48]

• Indication: Delineate exact extent of avascular retina before laser treatment
• Phases:
  • "Early arterial phase (10-15 sec): Highlights vascular-avascular junction"
  • "Late venous phase (30-60 sec): Shows leakage from neovascular vessels (confirms Plus disease activity)"
• Clinical use: Primarily research/complex cases (not routine screening)
• 2019 study: FA-guided laser treatment reduces retreatment rate by 15% vs. clinical exam alone [48]

Monitoring Timetable (UK Guidelines) [15]

Differential Diagnosis

Screening Timetable Matrix (UK Guidelines) [15]

Guideline for First Examination based on Gestational Age:

Key Principle: We do not screen before 31 weeks PMA because the vascularization is too immature to develop ROP, and the pupil is difficult to dilate.

Clinical Examination Findings: Detailed Descriptions

Normal Immature Retina (Pre-ROP):

• Appearance: Flat, grey-pink retina.
• Vessels: Spindle-shaped at advancing vascular front.
• Junction: Gradual fading of vessels into avascular retina (no distinct demarcation).
• Management: Continue screening every 2 weeks until vascularization complete.

Stage 1 ROP (Demarcation Line):

• Location: Junction between vascular and avascular retina.
• Appearance: Thin, flat, white line (like a pencil line drawn on the retina).
• Vessel Pattern: Vessels approach line then stop abruptly (no arborization or branching).
• Tortuosity: Normal vessel caliber and course.
• Clinical Significance: Mild disease. 80-90% spontaneous regression. [1,3]
• Management: Review in 1-2 weeks depending on zone.

Stage 2 ROP (Ridge):

• Location: At vascular-avascular junction (replaces demarcation line).
• Appearance: Elevated ridge rising from plane of retina (3-dimensional structure).
• Color: Pink to white (depending on vascularity).
• Width: Can vary from narrow "speed bump" to broad plateau.
• Vessels: May see "popcorn" tufts of vessels at base of ridge.
• Clinical Significance: 60-70% spontaneous regression if no Plus. [1,3]
• Management: Weekly review. Watch closely for Plus disease development.

Stage 3 ROP (Extraretinal Fibrovascular Proliferation):

• Location: Arising from the ridge, growing anteriorly into vitreous.
• Appearance: Red, ragged new vessels growing off the ridge (like moss on a tree branch).
• Extension: Can be mild (few clock hours) or circumferential (entire 360°).
• Clock Hours: Documented as "Stage 3 in X clock hours" (e.g., "Stage 3 in 5 clock hours").
• Vitreous Haze: May see mild vitreous hemorrhage from friable neovascular vessels.
• Clinical Significance: HIGH RISK. Requires weekly or more frequent review. [7,9]
• Management: If Plus disease present → Treat immediately. If no Plus → Close observation.

Plus Disease (The "Activity Marker"):

• Definition: Venous dilatation + arteriolar tortuosity in ≥2 quadrants of posterior pole. [9]
• "Standard Photo": ICROP reference image (approximate threshold).
• Arterial Changes:
  • Increased tortuosity (corkscrew appearance).
  • Vessels "wiggle" rather than follow smooth radial course from disc.
• Venous Changes:
  • Dilatation (wider caliber than normal for PMA).
  • Dark, engorged appearance.
• "Pre-Plus": Vascular abnormalities present but not meeting Plus threshold.
  • Clinical Dilemma: Inter-observer variability HIGH for Pre-Plus diagnosis. [9]
• Iris Vascular Engorgement: Sometimes visible (dilated radial iris vessels).
• Vitreous Haze: Inflammatory cells from active angiogenesis.
• Clinical Significance: Plus disease = ACTIVE disease engine. Greatest risk factor for progression. [7,9]

Aggressive ROP (A-ROP):

• Location: Zone I or Posterior Zone II.
• Appearance: Often FLAT neovascularization (not elevated ridge).
  • "Sheet" of new vessels rather than discrete ridge-proliferation pattern.
• Plus Disease: Severe (often described as "++ Plus").
• Hemorrhages: Frequent (pre-retinal, intra-retinal, vitreous).
• Speed of Progression: Can progress from no ROP to Stage 4 in 7-10 days. [9]
• "Posterior ROP": Historic term (AP-ROP) now expanded to A-ROP since can occur outside true posterior pole.
• Clinical Significance: OPHTHALMOLOGIC EMERGENCY. Treat within 24-48 hours. [7,9]

Stage 4 ROP (Partial Detachment):

• Appearance: Grey, elevated retina (no longer in contact with underlying RPE).
• Configuration:
  • 4A (Extrafoveal): Peripheral detachment, fovea still attached (concave detachment centered on ridge).
  • 4B (Foveal): Macula detached (wider detachment extending posteriorly).
• Fold Patterns: Can see retinal folds radiating from traction point.
• Vitreous: Often hazy from hemorrhage and inflammation.
• Clinical Significance: Poor prognosis even with surgery if 4B (foveal detachment). [24]

Stage 5 ROP (Total Detachment):

• Appearance: Complete retinal detachment, funnel configuration.
• Funnel Types:
  • Open Funnel: Anterior and posterior retina still have some separation (better prognosis).
  • Closed Funnel: Retina completely collapsed, touching itself (very poor prognosis).
• Anterior Segment Changes (Stage 5C - ICROP3): [9]
  • Shallow anterior chamber (lens pushed forward).
  • Iris rigidity (ischemia).
  • Corneal haze/edema.
  • Secondary angle-closure glaucoma.
• Leukocoria: "White pupil reflex" (classic late finding).
• Clinical Significance: Surgical emergency but functional outcomes very poor. [24]

Regression Patterns (Favorable):

• Vascular Maturation: Vessels grow past former ridge site, gradually reaching ora serrata.
• Ridge Flattening: Elevated ridge becomes flat, scar-like line.
• Vessel Changes:
  • Straightening of previously tortuous vessels.
  • Normalization of venous caliber.
• Peripheral Changes: May leave avascular far periphery (permanent).
• Documentation: "Regressed ROP, Zone X, formerly Stage Y" (for medical records).

Regression Patterns (Unfavorable):

• Temporal Vascular Dragging: Vessels pulled temporally toward ridge (macular ectopia).
• Retinal Folds: Permanent folds radiating from peripheral scar.
• Lattice Degeneration: Peripheral retinal thinning (predisposes to adult detachment). [26]
• Pigmentary Changes: RPE hypertrophy/atrophy at former ridge sites.

---

6. Management

Prevention (The Best Medicine)

Oxygen Targeting:

• Target SpO2 range: 91-95% (for infants less than 32 weeks GA). [4]
• Alarm limits set tight (lower limit 89%, upper limit 95%).
• Evidence: The SUPPORT trial (2010) showed that lower oxygen targets (85-89%) reduced severe ROP but increased mortality and NEC. [4] The NeOProM meta-analysis (2016) confirmed 91-95% as the optimal "safety zone". [17]

Nutritional Optimization:

• High protein delivery (target 4-4.5g/kg/day) to maximize IGF-1. [12]
• Breast milk (contains growth factors including IGF-1).
• Early aggressive nutrition reduces incidence of treatment-requiring ROP.

Minimize Oxygen Fluctuations:

• Oxygen variability (frequent swings between hypoxia and hyperoxia) is independently associated with severe ROP. [18]
• Use of automated oxygen control (servo-control) may reduce ROP incidence.

Treatment Indications (ETROP Criteria)

Treat "Type 1 ROP": [7] Any of the following:

1. Zone I: Any Stage (1, 2, or 3) with Plus disease.
2. Zone I: Stage 3 (even without Plus).
3. Zone II: Stage 2 or 3 with Plus disease.

Timing: Treatment must be performed within 48-72 hours of diagnosis. [7]

Why 48-72 hours? [7,43]

• Type 1 ROP can progress to Stage 4 (retinal detachment) within 1 week if untreated
• ETROP study showed no benefit to treating immediately vs. within 48 hours, but outcomes worsened after 1 week delay [7]
• Logistics: Allows time for consent, optimization of infant (stop feeds if anesthesia needed), and scheduling

Timing Controversies and Updates: [43,44]

1. Ultra-early treatment (less than 24 hours)?

• Some centers advocate treating A-ROP within 24 hours (vs. 48 hours for Type 1) [43]
• Rationale: A-ROP can progress faster than classic Type 1 ROP
• Evidence: Retrospective data suggest better outcomes with treatment within 24h for Zone I A-ROP [43]
• Current consensus: A-ROP should be treated "urgently" (24-48h), Type 1 ROP within 48-72h [9,43]

2. Can we delay treatment for unstable infants?

• Clinical dilemma: 23-24 week infant with Type 1 ROP but requiring high ventilatory support (MAP > 12, FiO2 > 60%)
• Risk-benefit analysis: [44]
  • "Anesthesia risk: 1-3% mortality/severe morbidity in extremely unstable infants"
  • "ROP progression risk: 15-25% progression to Stage 4 if delayed > 1 week"
• Solution: Use anti-VEGF with topical anesthesia (no intubation required) [6,44]
• If anti-VEGF unavailable and infant too unstable for laser: accept short delay (3-5 days) with daily monitoring, treat as soon as stable [44]

3. Weekend vs. Weekday treatment:

• Retrospective studies show no difference in outcomes for Friday diagnosis + Monday treatment (within 72h window) [45]
• However, A-ROP or rapidly progressive disease should not wait for weekend to pass
• Practical guidance: Routine Type 1 ROP can be scheduled for next available list (within 72h); A-ROP requires urgent intervention (including weekends/nights) [45]

Do NOT Treat "Type 2 ROP" (Watch and Wait):

• Zone I, Stage 1 or 2, No Plus.
• Zone II, Stage 3, No Plus.
• Monitor closely (weekly) as these can convert to Type 1.

Clinical Note: The ETROP study (2003) established that early treatment of "high-risk prethreshold ROP" (now called Type 1) reduced unfavorable visual outcomes from 19.5% to 14.5% and structural outcomes from 15.6% to 9.1% compared to conventional threshold treatment. [7]

ETROP Study Deep Dive (2003) [7,38]

Background:

• Prior to ETROP, the standard was the CRYO-ROP threshold (Stage 3+ in 5 contiguous or 8 cumulative clock hours with Plus in Zone I/II).
• Problem: By the time "threshold" was reached, 50% of untreated eyes had already progressed to unfavorable outcomes. [7]

Study Design:

• Multicenter RCT (26 centers, USA)
• Population: 401 infants with bilateral high-risk prethreshold ROP
• Intervention: Early treatment (at prethreshold) vs. conventional management (wait for threshold)
• Primary outcome: Visual acuity at 9 months corrected age (Teller acuity cards)

Key Findings: [7]

1. Visual Acuity Benefit:
   • Unfavorable visual acuity (worse than 20/200): 14.5% (early) vs. 19.5% (conventional), p=0.01
   • Number needed to treat (NNT) = 20 to prevent one case of poor vision
2. Structural Benefit:
   • Unfavorable structure (retinal fold/detachment): 9.1% (early) vs. 15.6% (conventional), pless than 0.001
   • NNT = 15 to prevent one structural complication
3. Zone I Benefit:
   • Greatest benefit in Zone I disease (unfavorable outcome 55% conventional vs. 15% early treatment)
   • Zone I Plus disease had 65% unfavorable outcome if untreated [7]

Type 1 ROP Definition (ETROP Criteria): [7] The study created the still-used "Type 1 ROP" definition (treat immediately):

• Zone I: Any stage with Plus
• Zone I: Stage 3 without Plus
• Zone II: Stage 2 or 3 with Plus

Type 2 ROP (observe closely, may convert to Type 1):

• Zone I: Stage 1 or 2 without Plus
• Zone II: Stage 3 without Plus

Long-term Follow-up (15 years): [38]

• Visual acuity benefit of early treatment persisted to age 15
• Myopia rates similar in both groups (~70%)
• Early treatment group had better binocular vision (stereopsis)

Clinical Impact:

• ETROP criteria became global standard
• Shifted practice from "wait and see" to "proactive early intervention"
• Reduced blindness from ROP by ~35% in developed countries [38]

Treatment Modalities

1. Laser Photocoagulation (The Gold Standard)

Method: Diode laser (810nm) or argon laser ablation of the avascular (peripheral) retina. [5,7]

Mechanism:

• By destroying the hypoxic peripheral avascular retina, the source of VEGF is eliminated.
• The central vessels stop proliferating abnormally and regress.
• Scar tissue formation stabilizes.

Technique:

• "Near confluent" burns (500-1000 μm spots, spaced 0.5-1 burn width apart).
• Cover entire avascular retina 360 degrees from ridge to ora serrata.
• Usually requires intubation and general anesthesia (or sedation with ketamine).
• Laser indirect ophthalmoscope or slit-lamp delivery system.

Anatomical Success: > 90% for Type 1 ROP. [5,7]

Advantages:

• Definitive, permanent treatment.
• Recurrence is rare (less than 5%).
• Decades of safety data.

Disadvantages:

• Destroys peripheral vision: Lifelong tunnel vision (visual field loss). [5]
• High incidence of myopia: 60-80% develop myopia (-5.00 to -10.00D). [19]
• Anesthetic risk: Requires intubation in fragile preterm infants.
• Cannot treat anterior Zone I: Laser requires view to periphery; if disease is too posterior or media is hazy, laser is impossible.

2. Anti-VEGF Intravitreal Injection

Agents:

• Bevacizumab (Avastin): 0.625mg (0.025mL). Most common global agent. Off-label use (originally for colon cancer). [6]
• Ranibizumab (Lucentis): 0.2mg (0.02mL). FDA-approved for ROP in 2022 based on RAINBOW trial. [20]
• Aflibercept (Eylea): 0.4mg (0.01mL). Emerging evidence (BUTTERFLEY trial ongoing).

Mechanism: Monoclonal antibody that binds VEGF-A, neutralizing the angiogenic drive within hours. Plus disease resolves often within 24-48 hours. [6]

Technique:

• Sterile prep (povidone-iodine 5%).
• Intravitreal injection at pars plicata (1.5-2mm posterior to limbus).
• 30-gauge needle.
• Topical anesthesia (no general anesthesia required).
• Bilateral injections typically performed same session.

Indications (Preferred over Laser):

• Zone I Disease: Laser causes extensive peripheral field loss; injection preserves peripheral retina. [6,20]
• Aggressive ROP (A-ROP): Laser is often too slow to act; injection provides rapid VEGF suppression.
• Media Haze: If pupil won't dilate or view is hazy (vitreous hemorrhage), laser is impossible.
• Unstable infant: Cannot tolerate prolonged anesthesia for laser.

Evidence:

• BEAT-ROP (2011): Bevacizumab showed significant benefit for Zone I disease (recurrence 6% vs 42% for laser). No difference for Zone II disease. [6]
• RAINBOW (2019): Ranibizumab 0.2mg was non-inferior to laser with fewer ocular structural adverse events and better peripheral retinal preservation. [20]

2024 Network Meta-Analysis: [39,40]

• 68 studies, 12,356 eyes analyzed comparing bevacizumab, ranibizumab, aflibercept vs. laser
• Retreatment rates:
  • "Laser: 3-5% (gold standard reference)"
  • Bevacizumab 0.625 mg: 8-12%
  • Ranibizumab 0.2 mg: 5-8%
  • Aflibercept 0.4 mg: 4-7%
• Zone-specific findings: [39]
  • "Zone I: All anti-VEGF agents superior to laser (lower retreatment, better peripheral vision)"
  • "Zone II: Laser and anti-VEGF similar efficacy; laser preferred due to definitive single treatment"
• Refractive outcomes: [40]
  • "Laser: High myopia (mean -6.5D at age 5)"
  • "Anti-VEGF: Moderate myopia (mean -3.2D), preserves normal eye growth"
• Dose-response relationship: [39]
  • Lower doses (bevacizumab 0.25mg, ranibizumab 0.1mg) associated with higher reactivation
  • Higher doses (bevacizumab 1.25mg) no additional benefit, more systemic VEGF suppression

Advantages:

• Preserves peripheral vision (avascular retina can continue to vascularize normally after injection). [6,20]
• Minimal anesthetic stress (topical only).
• "Rescue" therapy for eyes that would otherwise be blind (posterior Zone I).

Disadvantages:

• Late Reactivation: ROP can recur as late as 60-70 weeks PMA (months after injection). [21] This necessitates prolonged follow-up (until full vascularization, often 6-12 months).
• The "Crunch" (Tractional Detachment): In eyes with severe fibrovascular traction, rapid VEGF withdrawal causes scar contraction, snapping the retina off.
• Systemic VEGF Suppression: Serum VEGF levels drop for 8-12 weeks. [22] VEGF is needed for lung/brain/kidney maturation. Long-term neurodevelopmental safety is still debated (no definitive harm proven to date, but theoretical concern).
• Endophthalmitis Risk: Rare but devastating (less than 0.1%). [23]
• Need for Prolonged Surveillance: Cannot discharge from eye clinic at 40 weeks like laser-treated babies.

Dosing Comparison:

3. Surgical Management (Stage 4/5)

Indications: Retinal detachment (Stage 4B, 5).

Techniques:

• Vitrectomy: Remove tractional vitreous gel and cut scar tissue (membrane peeling). Lens-sparing vitrectomy in infants is challenging.
• Scleral Buckle: External silicone band to push scleral wall against retina (counteracts traction).
• Combined Vitrectomy-Buckle: For advanced Stage 4B/5.

Prognosis:

• Anatomical Success (reattachment): ~50-60% for Stage 4. [24]
• Visual Success: Very poor (ambulatory vision only, often less than 6/60). Foveal damage is usually irreversible by Stage 5.
• Goal: Often "eye preservation" and prevention of phthisis (shrinkage), rather than functional vision.

Timing: Controversial. Some advocate early surgery for Stage 4A (fovea-on), others wait until Stage 5 stabilization.

Management Algorithm (ASCII Flowchart)

┌─────────────────────────────┐
│  Preterm Infant less than 32w or     │
│  less than 1500g Birth Weight        │
└──────────┬──────────────────┘
           │
           ▼
┌─────────────────────────────┐
│  First ROP Screen at:       │
│  4 weeks or 31 weeks PMA    │
│  (whichever later)          │
└──────────┬──────────────────┘
           │
           ▼
       ┌───┴────┐
       │        │
   NO ROP    ROP Present
       │        │
       │        ▼
       │   ┌────────────────────┐
       │   │ Classify:          │
       │   │ Zone, Stage, Plus  │
       │   └────┬───────────────┘
       │        │
       │    ┌───┴─────┐
       │    │         │
       │  Type 2   Type 1
       │    │         │
       │    │         ▼
       │    │   ┌──────────────────┐
       │    │   │ TREAT within 48h │
       │    │   │ - Laser (Zone II)│
       │    │   │ - Anti-VEGF (Z I)│
       │    │   └──────┬───────────┘
       │    │          │
       │    ▼          ▼
       │  Monitor   Follow-up
       │  Weekly    Weekly x4
       │    │       Then tailored
       │    │          │
       └────┴──────────┴──────────▶
          
       Full Vascularization
       (Discharge from ROP service)

Post-Treatment Care

After Laser:

• Antibiotics: Topical chloramphenicol 0.5% or tobramycin 0.3% QDS x 3-5 days.
• Follow-up: Check at 1 week for regression, then 2 weeks, 4 weeks, 3 months, 6 months.
• Discharge Criteria: Full peripheral vascularization and regression of active disease (usually by 6 months corrected age).

After Anti-VEGF:

• Antibiotics: Topical (as above).
• Follow-up: Weekly checks for first 4 weeks (critical period for reactivation), then every 2 weeks until full vascularization. [21]
• Discharge Criteria: Full peripheral vascularization to ora serrata (often not until 12-18 months chronological age).
• Parental Education: MUST emphasize the need for prolonged follow-up and risk of late recurrence.

---

7. Complications

Immediate (Procedural)

Examination-Related:

• Conjunctival Tear/Haemorrhage: Common (10-20%) and benign.
• Corneal Abrasion: From speculum or scleral depressor.
• Bradycardia/Desaturation: Vagal response (20-30% of exams). [25]

Laser-Related:

• Vitreous Haemorrhage: Laser rupture of neovascular vessels (5-10%).
• Cataract: Lens touch during laser (permanent damage, less than 1%).
• Iris Damage: Pupillary margin burns (rare).

Anti-VEGF-Related:

• Endophthalmitis: Devastating intraocular infection (less than 0.1%). [23] Requires intravitreal antibiotics.
• Vitreous Haemorrhage: Needle strike (1-2%).
• Lens Injury: Cataract from needle touch (less than 0.5%).
• Acute Tractional Detachment: "Crunch" phenomenon in fibrotic cases (1-3%).

Short-Term (Within First Year)

• ROP Recurrence/Reactivation: 5-10% after laser, 10-20% after anti-VEGF. [21]
• Progression to Stage 4/5: Despite treatment, 2-5% progress to detachment. [7]
• Anterior Segment Changes: Iris rigidity, shallow anterior chamber, angle closure (especially Stage 4/5).

Long-Term (Ocular)

Refractive Errors:

• Myopia: Extremely common, especially after Laser (~70-80%). [19] Moderate to high myopia (-3.00 to -12.00D).
• Anisometropia: Unequal prescription between eyes, leading to amblyopia (lazy eye).
• Astigmatism: Irregular corneal shape from retinal traction.

Strabismus (Squint):

• Incidence: 30-50% in ROP survivors. [19]
• Mechanism: Retinal dragging (ectopic fovea), anisometropia, cortical visual impairment.

Visual Field Loss:

• Constricted peripheral fields from laser scars. [5]
• Peripheral retinal ablation destroys rod photoreceptors (night vision and peripheral awareness impaired).

Retinal Complications:

• Retinal Folds/Dragging: Temporal dragging of macula (macular ectopia).
• Late Retinal Detachment: Can occur in adulthood (10-20% lifetime risk). [26]
• Lattice Degeneration: Peripheral retinal thinning, predisposing to tears/detachment.

Glaucoma:

• Angle-closure glaucoma (especially Stage 4/5 with anterior segment changes).
• Incidence: 5-10% in severe ROP. [26]

Cortical Visual Impairment (CVI):

• Brain-based vision loss due to concurrent IVH/periventricular leukomalacia (PVL).
• ~20% of extremely preterm infants have CVI independent of ROP severity. [27]

Systemic (Long-Term)

Neurodevelopmental:

• Severe ROP is often a marker for a "sick brain" (shared risk factors: extreme prematurity, IVH, PVL, sepsis).
• Children with treated ROP have lower average Bayley scores than preterm peers without ROP. [27]
• Cerebral palsy, developmental delay, autism spectrum disorder all more common.

Cardiovascular:

• Preterm infants with ROP have higher rates of systemic hypertension in childhood/adulthood. [28]
• Mechanism: Shared vascular pathology (endothelial dysfunction).

---

8. Prognosis & Outcomes

Visual Outcome

Spontaneous Regression (No Treatment):

• > 90% of all ROP regresses without treatment. [1,3]
• Visual prognosis is good, though risk of myopia/squint remains higher than term peers.
• Even regressed ROP leaves subtle changes: straightening of vessels, peripheral avascularity.

Treated (Type 1 ROP):

• Anatomical Success: > 90% avoid retinal detachment. [5,7]
• Central Vision: Good (6/12 to 6/9) in majority if macula spared.
• Peripheral Vision: Impaired after laser (tunnel vision). Better preserved after anti-VEGF. [20]
• Need for Glasses: > 80% require spectacles (myopia, astigmatism). [19]

Stage 4 (Partial Detachment):

• Stage 4A (Fovea-on): With surgery, 50-60% achieve ambulatory vision (6/60 or better). [24]
• Stage 4B (Fovea-off): Poor prognosis. Vision usually less than 6/60 even with surgery.

Stage 5 (Total Detachment):

• Functional blindness is the norm (light perception or hand movements at best).
• Goal of surgery is often "eye preservation" rather than sight (prevent phthisis, pain, cosmesis).

"Late Reactivation" After Anti-VEGF

• With the increasing use of Anti-VEGF, we are seeing ROP recur as late as 60-70 weeks PMA (up to 6 months after initial injection). [21]
• Mechanism: VEGF suppression is temporary (4-8 weeks). If peripheral retina has not yet fully vascularized when VEGF levels recover, neovascularization can restart.
• Critical Lesson: Do not discharge an Anti-VEGF baby from eye clinic at 40 weeks. They must be watched until fully vascularized to ora serrata (often 6-12 months adjusted age). [21]

Long-Term Follow-Up Recommendations

All ROP (Treated or Regressed):

• Eye exam at 6 months corrected age: Refraction, cycloplegic exam.
• Annual eye exams lifelong: Monitor for:
  • Myopia progression
  • Strabismus
  • Amblyopia
  • Late retinal detachment
  • Glaucoma

Severe ROP (Stage 3+):

• Increased vigilance for late detachment.
• Education: Patients should seek urgent ophthalmology review for new floaters, flashes, or field loss (symptoms of retinal tear/detachment).

---

9. Evidence & Guidelines

Key Guidelines

1. Royal College of Ophthalmologists (RCOphth) — Guideline for the Screening and Treatment of Retinopathy of Prematurity (2022). [15] Defines UK screening matrix (31w/1251g).
2. American Academy of Pediatrics (AAP) — Screening Examination of Premature Infants for Retinopathy of Prematurity (2018). [3] Defines US matrix (30w/1500g).
3. International Council of Ophthalmology (ICO) — ICO Guidelines for Diabetic Eye Care (includes ROP section, 2017).
4. World Health Organization (WHO) — Guidelines for Screening and Treatment of ROP in Middle-Income Countries (2022). [10]

Landmark Trials

ETROP (Early Treatment for ROP) Study (2003) [7]

• Question: Should we treat at "Threshold" (old criteria - 50% risk of detachment) or "Pre-Threshold" (earlier)?
• Design: Multicenter RCT, 401 infants.
• Finding: Treating "high risk pre-threshold" (now called Type 1) reduced:
  • Unfavorable visual acuity from 19.5% to 14.5% (p=0.01).
  • Unfavorable structural outcome from 15.6% to 9.1% (pless than 0.001).
• Clinical Impact: Set the current Standard of Care (Treat Type 1 within 48-72h).

BEAT-ROP (2011) [6]

• Bevacizumab Eliminates the Angiogenic Threat of ROP.
• Question: Is Avastin (bevacizumab) better than Laser for Zone I ROP?
• Design: Multicenter RCT, 150 infants with Stage 3+ ROP.
• Finding: Anti-VEGF showed significant benefit for Zone I disease:
  • Recurrence: 6% (anti-VEGF) vs 42% (laser), p=0.003.
  • No difference for Zone II (recurrence ~20% both groups).
• Clinical Impact: Validated injections as superior for posterior (Zone I) disease. Changed practice worldwide.

SUPPORT Trial (2010) [4]

• Question: Oxygen targets 85-89% vs 91-95% in extremely preterm infants (less than 28w).
• Design: Multicenter RCT, 1316 infants.
• Finding:
  • Low oxygen group (85-89%): Less severe ROP (8.6% vs 17.9%, pless than 0.001).
  • BUT: Higher mortality (19.9% vs 16.2%, p=0.04) and more NEC.
• Clinical Impact: Established 91-95% as the "safety" sweet spot: preventing blindness without causing death.

NeOProM Meta-Analysis (2016) [17]

• Neonatal Oxygenation Prospective Meta-analysis.
• Combined 5 trials (SUPPORT, BOOST-II, COT, etc.), 4965 infants.
• Finding: Confirmed 91-95% SpO2 targets optimal for balancing mortality and ROP risk.

RAINBOW Trial (2019) [20]

• Ranibizumab compared with laser therapy for the treatment of Very Low Birthweight Infants with ROP.
• Question: Ranibizumab (Lucentis) vs Laser for Type 1 ROP.
• Design: Phase 3 RCT, 224 infants.
• Finding:
  • Ranibizumab 0.2mg was non-inferior to laser (treatment success ~80% both groups).
  • Fewer ocular structural adverse events (12% vs 23%, p=0.03).
  • Better peripheral retinal preservation (90% vs 60% fully vascularized).
• Clinical Impact: Led to FDA approval of ranibizumab for ROP (2022).

Evidence Strength Table

---

10. Special Populations & Emerging Therapies

The "Third Epidemic" in Middle-Income Countries

Context:

• First Epidemic (1940s-50s): Uncontrolled oxygen in high-income countries (before link discovered).
• Second Epidemic (1970s-80s): Improved survival of extreme preterm infants with advent of NICU.
• Third Epidemic (2000s-present): Middle-income countries (India, China, Brazil, Eastern Europe, Latin America). [10,11]

Characteristics: [11]

• ROP occurring in larger, more mature infants (28-34 weeks, 1200-1800g).
• Unmonitored oxygen in under-resourced NICUs (lack of blenders, pulse oximeters, alarm systems).
• Inconsistent screening (shortage of trained ophthalmologists, no RetCam, late referrals).
• Aggressive disease (Zone I, A-ROP) in infants who would not develop ROP in high-income settings.

Public Health Response:

• WHO ROP guidelines for low/middle-income countries (broader screening criteria). [10]
• Telemedicine (e-ROP) programs (image capture by nurses, remote reading by experts).
• Training programs for ophthalmologists and neonatologists.

Emerging Therapies & Research

Propranolol (Beta-Blocker):

• Oral or topical propranolol may reduce progression to severe ROP. [29]
• Mechanism: Inhibits VEGF signaling and reduces angiogenesis.
• Status: Promising early trials, but not yet standard of care (PROP-ROP trial ongoing).

IGF-1 Supplementation:

• Recombinant IGF-1/IGFBP-3 (rhIGF-1) to normalize levels in preterm infants. [12]
• Hypothesis: Maintaining physiological IGF-1 levels allows normal (not pathological) angiogenesis.
• Status: Phase 2 trials completed, awaiting larger studies.

Stem Cell Therapy:

• Intravitreal or systemic mesenchymal stem cells (MSCs) to promote normal vascular growth and reduce inflammation.
• Status: Preclinical/early clinical trials.

Gene Therapy:

• Targeting HIF-VEGF pathway.
• Status: Preclinical research only.

Automated Oxygen Control:

• Servo-controlled oxygen delivery systems to minimize fluctuations. [18]
• Status: Increasingly adopted in NICUs, may reduce ROP incidence.

---

11. Patient/Layperson Explanation

What is Retinopathy of Prematurity (ROP)?

The retina is the "camera film" at the back of the eye. Its blood vessels usually finish growing just before a baby is born full-term (40 weeks). When a baby is born early, these vessels are not finished. Because the baby is now breathing air (which has more oxygen than the womb) and receiving oxygen support, the blood vessels get "confused" and stop growing. Later, as the eye gets bigger, the retina gets hungry for oxygen and sends out "SOS signals" (VEGF). These signals make new vessels grow too fast and too wildly. This wild growth can cause scarring and pull the retina off the back of the eye. [1,8]

Is my baby at risk?

We screen all babies born more than 8-9 weeks early (less than 31-32 weeks) or very small (less than 1.5kg). [3,15] The first check is usually when the baby is about 4-6 weeks old.

What happens during screening?

An eye specialist (ophthalmologist) will look at your baby's eyes:

1. We put drops in the eyes to make the pupils big (dilate). It takes about an hour to work.
2. We use a special headset and a small lens to look into the eye.
3. We sometimes use a small tool to gently push on the eyelid to see the edges of the retina.
4. It is bright and uncomfortable, so the baby will likely cry. We use numbing drops and sugar water (sucrose) to keep them as calm as possible. It does not damage the eye.
5. The exam takes 5-10 minutes per eye. [16]

What if ROP is found?

• Mild ROP (Stage 1-2): We watch carefully (every 1-2 weeks). Most babies (> 90%) get better on their own as they grow. [1,3]
• Severe ROP (Type 1): We treat immediately (within 2-3 days) to stop blindness.

Treatment Options

Laser:

• We use a laser to make tiny burns on the edges of the retina.
• This stops the "SOS signals" (VEGF). [5,7]
• It saves the central vision but might reduce side (peripheral) vision.
• The baby usually needs a breathing tube (general anesthesia) for the procedure.

Injections (Anti-VEGF):

• We inject a medicine (bevacizumab or ranibizumab) into the eye to block the "SOS signals". [6,20]
• This is quicker and less stressful (no breathing tube).
• The baby can go home the same day.
• IMPORTANT: Requires very careful follow-up for many months (the ROP can come back weeks or months later). [21]

Long-Term Outlook

Glasses:

• Babies with ROP are much more likely to be short-sighted (myopia) and need glasses early in life (70-80%). [19]

Squint:

• They often develop a "turn" in the eye (strabismus, 30-50%). [19]

Eye Checks:

• They will need eye checks every year until they start school, then regularly throughout life. [26]

Vision:

• If ROP is caught early and treated, most babies have good central vision (can read, watch TV, recognize faces).
• Peripheral vision may be reduced (especially after laser). [5,20]

---

12. Clinical FAQs (Parent Handout)

Q: Did the light in the NICU cause this? A: No. We used to think bright lights caused ROP, and we covered incubators with blankets. Studies have shown that ambient light does not cause ROP. [30] It is purely due to oxygen levels and immaturity.

Q: Will my baby go blind? A: It is very unlikely in a modern unit. With screening and treatment, the risk of blindness is less than 1%. [3,7] However, your child will likely need glasses for short-sightedness when they start school.

Q: Can we fly with ROP? A: If the ROP is active or the retina is detached, air travel (pressure changes) can be risky if there is gas inside the eye from surgery. If it is stable/regressed, flying is safe. Always check with your ophthalmologist before booking flights.

Q: Does it affect the other eye? A: Yes, ROP is almost always bilateral (both eyes) and usually symmetrical (similar severity). [1]

Q: My baby had an injection (Anti-VEGF). Can we stop eye checks now? A: No. This is VERY important. After injections, the ROP can come back weeks or months later (late reactivation). [21] Your baby needs weekly checks for at least 4 weeks, then regular checks until the blood vessels have fully grown (often 6-12 months). Missing a check could lead to blindness.

Q: Will ROP affect my baby's brain development? A: ROP itself does not damage the brain. However, babies who develop severe ROP are often very premature and may have had other problems (brain bleeds, infections) that can affect development. [27] Your baby will be closely monitored by the developmental team.

Q: Can my child play sports? A: Yes, in most cases. However, if your child had severe ROP (especially Stage 4-5 or extensive laser), they may be at higher risk of retinal detachment from head trauma. Contact sports (boxing, rugby) should be discussed with the ophthalmologist. Most other sports are safe.

Q: Will my child need more than one treatment? A: Possibly. About 5-10% of babies need a second treatment (laser after failed injection, or vice versa). [21] This is why close monitoring is essential.

---

13. Medico-Legal Considerations

Duty of Care

Screening:

• Failure to screen an eligible infant (less than 1500g or less than 30-32w) is indefensible. [3,15]
• Inadequate follow-up (missed appointments, delayed exams) is a common source of litigation.

Documentation:

• Detailed documentation is mandatory (zone, stage, plus disease, clock hours involved).
• Digital imaging (RetCam) is medicolegal gold standard. [16]
• "Not documented = Not done" in court.

Treatment:

• Failure to treat Type 1 ROP within 72 hours is negligent. [7]
• Delayed referral (from community hospital to tertiary center) is high-risk.

Informed Consent:

• Parents must be counseled on:
  • Natural history of ROP (90% regression vs 10% progression). [1,3]
  • Treatment options (laser vs anti-VEGF).
  • Risks and benefits of each (peripheral vision loss with laser, late reactivation with anti-VEGF). [5,6,20,21]
  • Need for lifelong follow-up.

Common Pitfalls

1. Screening too early (less than 31w PMA): Wastes resources, causes unnecessary stress.
2. Stopping screening too soon: Must continue until fully vascularized (especially after anti-VEGF). [21]
3. Treating Type 2 ROP: Overtreatment. Type 2 should be observed, not treated. [7]
4. Discharging anti-VEGF baby at term: High risk of late reactivation. [21]
5. Poor communication: Parents not informed of ROP diagnosis or treatment plan.

---

14. Future Directions

Telemedicine & AI

e-ROP (Telemedicine Screening):

• Wide-field imaging (RetCam) performed by trained nurses.
• Images transmitted to remote expert for interpretation. [16]
• Benefit: Expands access in under-served areas (rural, middle-income countries).

AI-Assisted Diagnosis:

• Deep learning algorithms (i-ROP DL) can detect Plus disease with \u003e 90% accuracy. [31]
• May reduce inter-observer variability.
• Caution: Not yet ready for autonomous decision-making (still requires expert oversight).

2023 AI Performance Benchmarks: [31,34,49]

Clinical Translation Barriers: [49]

1. Dataset diversity: Most AI trained on Western populations; performance drops 10-15% on Asian/African cohorts [49]
2. Image quality dependence: AI accuracy falls to 70-75% with hazy media or poor focus
3. Legal liability: Who is responsible if AI misses Type 1 ROP? (unresolved medicolegal question)
4. Workflow integration: NICU staff resistance to uploading images to cloud-based AI platforms (privacy concerns)

Future Vision (2025-2030): [49]

• Autonomous screening: AI pre-screens all images → ophthalmologist reviews only flagged cases (50% workload reduction)
• Real-time grading: Smartphone-based RetCam + on-device AI → instant classification during exam
• Predictive algorithms: Combine retinal imaging + clinical data (weight gain, oxygen exposure) → predict progression to Type 1 ROP 2-3 weeks in advance

Biomarkers & Risk Prediction

WINROP Algorithm:

• Uses weekly weight gain and IGF-1 levels to predict severe ROP. [12]
• Sensitivity: ~90% for detecting treatment-requiring ROP.
• Potential: Could reduce number of stressful exams in low-risk infants.

Serum VEGF Levels:

• Low VEGF in first weeks (Phase 1) + high VEGF later (Phase 2) predicts severe ROP. [8]
• Not yet clinical standard (requires frequent blood draws).

Novel Biomarkers Under Investigation: [50,51]

WINROP Deep Dive (Clinical Application): [12,50]

• Algorithm inputs: Birth weight, gestational age, weekly weight measurements
• Output: Binary classification (High Risk / Low Risk for treatment-requiring ROP)
• Performance:
  • Sensitivity 100% (no false negatives) in Swedish validation cohort [50]
  • Specificity 40-50% (moderate false positive rate)
  • Could safely reduce screening exams by 30-40% in low-risk infants [50]
• Limitations:
  • Requires weekly weight data (may be unavailable if infant transferred between hospitals)
  • Not validated in Third Epidemic populations (larger babies with unmonitored oxygen)
  • Does not account for acute events (sepsis, NEC) that acutely increase risk

Personalized Medicine

• Genetic Risk Stratification: Polymorphisms in VEGF, IGF-1, and Norrin genes may predict ROP susceptibility.
• Pharmacogenomics: Tailoring anti-VEGF dose to individual infant characteristics (weight, VEGF levels, zone/stage).

---

15. Summary Table: Laser vs Anti-VEGF

---

16. Key Takeaways for Exams (MRCPCH/FRACP)

High-Yield Facts

1. Biphasic Pathophysiology:

   • Phase 1 (Hyperoxia): VEGF suppression → vessel arrest.
   • Phase 2 (Hypoxia): VEGF surge → neovascularization. [8]

2. Type 1 ROP (Treat within 48-72h): [7]

   • Zone I: Any stage with Plus, OR Stage 3 without Plus.
   • Zone II: Stage 2 or 3 with Plus.

3. Plus Disease = Activity: More important than Stage. [9]

4. BEAT-ROP: Anti-VEGF superior for Zone I (recurrence 6% vs 42%). [6]

5. SUPPORT: 91-95% SpO2 optimal (lower = more death, higher = more ROP). [4]

6. Late Reactivation: Anti-VEGF babies need follow-up until 60-70w PMA. [21]

7. Third Epidemic: Middle-income countries, larger babies (28-34w), unmonitored O2. [10,11]

8. IGF-1: Low levels predict severe ROP (WINROP algorithm). [12]

9. Long-term: 70-80% myopia, 30-50% strabismus, lifelong detachment risk. [19,26]

10. Differential: FEVR (full-term, family history), Norrie (XL, deaf, ID), Retinoblastoma (calcified mass).

Viva Voce Preparation: Common Examiner Questions

Q1: "Walk me through the pathophysiology of ROP using the VEGF-IGF-1 axis."

Model Answer: [8,12]

• Normal retinal vascularization requires VEGF (angiogenic driver) + IGF-1 (permissive factor)
• Preterm birth → Phase 1 (hyperoxia): Room air PaO2 60-100mmHg vs. intrauterine 30mmHg
  • High oxygen → HIF-1α degradation → VEGF suppression
  • Low IGF-1 (normally acquired transplacentally in 3rd trimester) → endothelial apoptosis
  • "Result: Vaso-obliteration (existing vessels disappear, new growth stops)"
• Phase 2 (hypoxia, 32-34w+): Neural retina matures metabolically
  • Avascular peripheral retina cannot meet oxygen demand → tissue hypoxia
  • Hypoxia → HIF-1α accumulation → massive VEGF upregulation
  • Improving nutrition → IGF-1 rises
  • High VEGF + IGF-1 = unregulated neovascularization (extraretinal fibrovascular proliferation)
• Phase 3 (cicatrization): Myofibroblasts in fibrovascular tissue contract → tractional retinal detachment

Q2: "A 25-week infant has Zone I Stage 2 with Pre-Plus disease. What do you do?"

Model Answer: [7,9]

• Classification: Type 2 ROP (Zone I Stage 1 or 2 without definite Plus = observe, not treat)
• BUT Pre-Plus is subjective (50-70% inter-observer disagreement) [36]
• Management:
  • Do NOT treat immediately (avoid overtreatment)
  • "Short-interval follow-up: Re-examine in 3-5 days (not 1 week)"
  • If truly borderline between Pre-Plus and Plus → get second opinion or serial imaging
  • If vascular changes progress to definite Plus → convert to Type 1, treat within 48h
  • If plateau or regress → continue weekly observation
• Rationale: Zone I location is high-risk, so cannot use standard 1-2 week intervals

Q3: "Why is Plus disease more important than Stage?"

Model Answer: [7,9]

• Plus disease = VEGF storm (severe arterial tortuosity + venous dilatation ≥2 quadrants)
• Indicates ACTIVE disease engine (high VEGF production)
• ETROP study showed Plus disease is the strongest predictor of progression [7]
• Example: Stage 3 WITHOUT Plus (Type 2) = watch → 70% spontaneous regression
• Example: Stage 2 WITH Plus (Type 1) = treat immediately → 25% progress to detachment if untreated
• Plus disease determines treatment urgency more than anatomical stage

Q4: "Parent asks: Why can't we discharge at 40 weeks after anti-VEGF injection?"

Model Answer: [21,32]

• Anti-VEGF suppresses VEGF temporarily (bevacizumab half-life 4-8 weeks in vitreous)
• When VEGF levels recover, if peripheral retina still avascular → neovascularization can RESTART
• Late reactivation documented as late as 60-70 weeks PMA (up to 6 months post-injection) [21]
• Unlike laser (permanent ablation), anti-VEGF allows peripheral vessels to continue growing
• Must follow until COMPLETE vascularization to ora serrata (often 55-65 weeks PMA)
• Premature discharge = medicolegal disaster (5% of ROP blindness historically from stopped screening) [42]

Q5: "How would you counsel parents about laser vs. anti-VEGF for Zone I ROP?"

Model Answer: [5,6,20,21]

Laser Pros:

• Definitive (recurrence less than 5%)
• Decades of safety data (ETROP gold standard) [7]
• Shorter follow-up (3-6 months)

Laser Cons:

• Zone I laser = extensive peripheral ablation → severe visual field loss (tunnel vision) [5]
• Requires general anesthesia (intubation risk in 23-24w infant)
• Higher myopia rate (70-80%, mean -6.5D) [19,40]

Anti-VEGF Pros:

• Preserves peripheral retina (vessels can vascularize normally after injection) [20]
• Topical anesthesia only (safer for unstable infant)
• Better refractive outcomes (40-50% myopia, mean -3.2D) [40]
• BEAT-ROP: Zone I recurrence 6% vs 42% for laser [6]

Anti-VEGF Cons:

• Late reactivation risk (10-20%) → need 6-12 month follow-up [21]
• Systemic VEGF suppression (serum levels drop 8-12 weeks) [22]
  • "Theoretical concern: VEGF needed for lung/brain/kidney development"
  • No proven harm to date, but long-term neurodevelopmental data limited
• Risk of "crunch" (tractional detachment from rapid scar contraction in fibrotic cases)

Recommendation for Zone I: Anti-VEGF preferred (BEAT-ROP evidence + vision preservation) [6,20] Recommendation for Zone II: Laser preferred (definitive, low recurrence) unless infant unstable for anesthesia

Q6: "Describe the Third Epidemic and how it differs from ROP in developed countries."

Model Answer: [10,11,35]

• First Epidemic (1940s-50s): Uncontrolled oxygen in high-income countries → ROP epidemic before link discovered
• Second Epidemic (1970s-80s): Improved survival of extreme preterm (less than 25w) with NICU advent
• Third Epidemic (2000s-present): Middle-income countries (India, China, Brazil, Eastern Europe)

Differences:

Public Health Solution: WHO ROP guidelines (2022) [10]

• Universal pulse oximetry (basic standard)
• Training in oxygen blending and SpO2 targeting
• Telemedicine screening (RetCam images, remote grading) [16,33]

---

---

18. Clinical Scenarios & Case-Based Learning

Scenario 1: Classic Zone II Type 1 ROP

Clinical Presentation:

• Infant: 25+3 weeks gestation, birth weight 680g, now 36 weeks PMA.
• History: Prolonged ventilation (4 weeks), oxygen requirements fluctuated 30-80% FiO2, poor weight gain (currently 1.2kg).
• Current Exam: Zone II, Stage 3 ROP with Plus disease in 8 clock hours (bilateral, symmetric).
• Findings: Markedly tortuous arterioles, dilated veins (>standard photo), ragged neovascularization at ridge.

Classification: Type 1 ROP (Zone II, Stage 3, Plus).

Management Decision:

• Immediate: Counsel parents (same day).
• Treatment: Laser photocoagulation within 48 hours (Zone II, so laser preferred over anti-VEGF). [5,7]
• Technique: 360° laser ablation of avascular retina, 2000-3000 burns per eye.
• Follow-up: 1 week post-laser (check for regression), then 2-4-6 week intervals.

Expected Outcome: > 90% chance of regression with preserved central vision. [5,7] Lifelong myopia and reduced peripheral vision expected.

---

Scenario 2: Aggressive Posterior ROP (A-ROP) - Treatment Dilemma

Clinical Presentation:

• Infant: 23+6 weeks gestation, birth weight 520g, now 32 weeks PMA.
• History: IVH Grade 3, late-onset sepsis (Staph epi), multiple blood transfusions, TPN-dependent.
• Previous Exam (1 week ago): Zone II, Stage 1, no Plus.
• Current Exam: Zone I, flat neovascularization with severe Plus (++ vascular tortuosity), intra-retinal hemorrhages, vitreous haze.

Classification: Aggressive ROP (A-ROP), Zone I. [9]

Management Decision:

• Urgency: Ophthalmologic EMERGENCY. Treat within 24-48 hours. [7,9]
• Treatment Choice: Intravitreal bevacizumab 0.625mg (preferred for Zone I disease). [6,20]
  • Rationale: Laser would ablate entire Zone I (massive visual field loss). Anti-VEGF preserves peripheral retina.
• Consent Issues: Discuss late reactivation risk (10-20%), need for prolonged follow-up (6-12 months), systemic VEGF suppression (theoretical concern). [21,22]
• Follow-up: Weekly exams for 4 weeks (critical period), then every 2 weeks until full vascularization (may take 60-70 weeks PMA). [21]

Expected Outcome: 85-90% regression with anti-VEGF in Zone I disease. [6,20] BUT 15-20% recurrence risk mandates vigilant follow-up.

---

Scenario 3: Late Reactivation After Anti-VEGF

Clinical Presentation:

• Infant: 24+2 weeks gestation, birth weight 590g.
• History: Treated with bilateral bevacizumab at 34 weeks PMA for Zone I, Stage 3, Plus ROP.
• Initial Response: Excellent. Plus disease resolved within 1 week. Vessels began maturing normally.
• Follow-up: Weekly exams showed progressive vascularization to Zone II by 45 weeks PMA.
• Discharge Plan: Paediatricians planned discharge from eye clinic at 50 weeks PMA.
• Current Presentation (62 weeks PMA): Parents noticed "baby doesn't track toys anymore."
• Exam: Zone II, Stage 3 neovascularization with Plus disease (NEW disease, not residual).

Classification: Late Reactivation of ROP post-anti-VEGF. [21]

Pathophysiology:

• Bevacizumab's half-life is ~4-8 weeks in vitreous.
• VEGF suppression is TEMPORARY.
• When VEGF levels recover, if peripheral retina still avascular → neovascularization can recur. [21,22]

Management Error: Should NOT have discharged at 50 weeks. Anti-VEGF babies need follow-up until COMPLETE vascularization to ora serrata (often 65-70 weeks PMA or beyond). [21]

Corrective Management:

• Re-treat: Laser photocoagulation now (avascular retina has had time to develop, can be lasered).
• Counsel Parents: Explain late reactivation risk (was preventable with proper follow-up).
• Follow-up: Continue until fully vascularized.

Lesson: "Anti-VEGF is not a discharge ticket at term." [21]

---

Scenario 4: Bilateral Asymmetric ROP - Decision-Making

Clinical Presentation:

• Infant: 26+1 weeks gestation, birth weight 750g, now 38 weeks PMA.
• Right Eye: Zone II, Stage 2, Plus disease (Type 1 ROP).
• Left Eye: Zone II, Stage 3, no Plus (Type 2 ROP).

Clinical Dilemma: Do we treat both eyes? Or only the right?

Evidence-Based Approach:

• Type 1 (Right Eye): MUST treat (ETROP criteria). [7]
• Type 2 (Left Eye): Watch and wait. Stage 3 without Plus does NOT meet treatment criteria. [7]
  • Risk of overtreatment (unnecessary ablation of peripheral retina).
  • BUT requires CLOSE observation (exam in 3-5 days) as can convert to Type 1.

Management Plan:

• Right Eye: Laser photocoagulation within 48 hours.
• Left Eye: Observation. Re-examine in 3-5 days.
  • If develops Plus → Treat.
  • If progresses to Stage 4 → Urgent treatment (laser or vitrectomy).
  • If regresses → Continue monitoring.

Parental Counseling: Explain asymmetry, rationale for differential treatment, and need for close observation.

---

Scenario 5: ROP in a "Big Baby" (Third Epidemic Pattern)

Clinical Presentation:

• Setting: Tertiary NICU in middle-income country.
• Infant: 32+4 weeks gestation, birth weight 1650g, now 39 weeks PMA.
• History: Rural district hospital birth, transferred at day 4 with respiratory distress. Oxygen given via nasal prongs ("oxygen as needed, sats not monitored"). No pulse oximetry available at referring hospital for first 2 weeks of life.
• Current Exam: Zone II, Stage 3 ROP with Plus disease (bilateral).

Classification: Type 1 ROP in an infant who would NOT have developed ROP in high-income setting (too mature, too large). [10,11]

Third Epidemic Characteristics: [10,11]

• Larger infants (28-34 weeks, > 1200g) developing ROP due to unmonitored oxygen.
• Lack of Resources: No blenders, no alarm limits, oxygen given "as needed."
• Late Presentation: First eye exam at 5-6 weeks (vs. 4 weeks in high-income settings).
• Aggressive Disease: Higher proportion of Zone I and A-ROP.

Management:

• Immediate Treatment: Laser or anti-VEGF (depending on resources and surgeon availability).
• Systemic Approach: Advocate for:
  • Pulse oximetry in ALL NICUs (basic standard of care).
  • Training for oxygen blending and SpO2 targeting (91-95%). [4]
  • ROP screening protocols (telemedicine if no local ophthalmologist). [16]

Public Health Lesson: ROP is preventable with proper oxygen management. [4,10,11]

---

Scenario 6: ROP in the Context of NEC and Sepsis

Clinical Presentation:

• Infant: 25+0 weeks gestation, birth weight 640g, now 35 weeks PMA.
• Complicated Course:
  • NEC requiring ileostomy at day 18.
  • Late-onset sepsis (E. coli) day 25.
  • IVH Grade 2 on cranial USS.
  • Multiple blood transfusions (5 units packed red cells).
• Exam: Zone II, Stage 3 ROP with Plus disease.

Pathophysiology Links: [13,14]

• NEC/Sepsis: Systemic inflammation → cytokine storm (IL-6, IL-8, TNF-α) → amplifies VEGF signaling.
• Blood Transfusions: Adult Hb (HbA) has lower oxygen affinity than fetal Hb (HbF) → increased tissue oxygen delivery (right shift of oxygen-dissociation curve) → relative hyperoxia → VEGF suppression in Phase 1. [14]
• IVH: Marker of general instability and brain injury (shared vascular pathology).

Clinical Significance: Infants with "stormy" NICU courses (sepsis, NEC, IVH) are at HIGHEST risk for severe ROP. [13]

Management: Treat Type 1 ROP as usual, BUT counsel parents about higher neurodevelopmental risk (not just eye outcomes). [27]

---

Scenario 7: Adult Presentation - Late Retinal Detachment

Clinical Presentation:

• Patient: 28-year-old woman, history of prematurity (26 weeks, ROP treated with laser age 3 months).
• Presentation: 3-day history of flashing lights (photopsia) and "curtain" over left vision.
• Exam: Lattice degeneration with horseshoe tear and inferior retinal detachment (macula-off).

Pathophysiology: [26]

• Regressed ROP leaves peripheral retinal changes (lattice, vitreoretinal adhesions).
• Lifetime risk of retinal detachment: 10-20% (vs. less than 1% in general population). [26]
• Highest risk: 20s-40s (vitreous liquefaction and posterior vitreous detachment).

Management:

• Urgent vitreoretinal surgery: Vitrectomy + laser/cryo retinopexy + gas tamponade.
• Prognosis: Macula-off detachment → poor visual outcome (often 6/60 or worse).

Prevention:

• Lifelong Eye Exams: All adults with ROP history should have annual dilated exams. [26]
• Patient Education: Seek urgent review for flashes, floaters, or field loss (warning signs of tear/detachment).

---

17. References

Primary Guidelines

1. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515-2526. doi:10.1056/NEJMra1208129 [PMID: 23268665]
2. Cayabyab R, Ramanathan R. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology. Neonatology. 2016;109(4):369-76. doi:10.1159/000444901 [PMID: 27251645]
3. Fierson WM; American Academy of Pediatrics Section on Ophthalmology. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018;142(6):e20183061. doi:10.1542/peds.2018-3061 [PMID: 30478242]

Landmark Trials

4. The SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959-1969. doi:10.1056/NEJMoa0911781 [PMID: 20472937]
5. McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology. 1991;98(5):576-580. doi:10.1016/s0161-6420(91)32262-4 [PMID: 2062493]
6. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615. doi:10.1056/NEJMoa1007374 [PMID: 21323540]
7. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684-1694. doi:10.1001/archopht.121.12.1684 [PMID: 14664921]

Pathophysiology & Mechanisms

8. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445-1457. doi:10.1016/S0140-6736(13)60178-6 [PMID: 23782686]
9. Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128(10):e51-e68. doi:10.1016/j.ophtha.2021.05.031 [PMID: 34247850]
10. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350(9070):12-14. doi:10.1016/S0140-6736(97)01107-0 [PMID: 9217715]
11. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74 Suppl 1:35-49. doi:10.1038/pr.2013.205 [PMID: 24366462]
12. Smith LE. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate. 2005;88(3):237-244. doi:10.1159/000087587 [PMID: 16210846]
13. Sood BG, Madan A, Saha S, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res. 2010;67(4):394-400. doi:10.1203/PDR.0b013e3181d01a36 [PMID: 20032809]
14. Dani C, Reali MF, Bertini G, et al. The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev. 2001;62(1):57-63. doi:10.1016/s0378-3782(01)00115-3 [PMID: 11245995]

Guidelines & Screening

15. Royal College of Ophthalmologists and Royal College of Paediatrics and Child Health. Guideline for the Screening and Treatment of Retinopathy of Prematurity. RCOphth; 2022. Available at: https://www.rcophth.ac.uk

Technology & Imaging

16. Quinn GE, Ying GS, Daniel E, et al. Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol. 2014;132(10):1178-1184. doi:10.1001/jamaophthalmol.2014.1604 [PMID: 25010141]

Oxygen & Prevention

17. Askie LM, Darlow BA, Finer N, et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. JAMA. 2018;319(21):2190-2201. doi:10.1001/jama.2018.5725 [PMID: 29872859]
18. Laptook AR, Salhab W, Allen J, Saha S, Walsh M. Pulse oximetry in very low birth weight infants: can oxygen saturation be maintained in the desired range? J Perinatol. 2006;26(6):337-341. doi:10.1038/sj.jp.7211500 [PMID: 16625328]

Long-Term Outcomes

19. O'Connor AR, Stephenson TJ, Johnson A, et al. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics. 2002;109(1):12-18. doi:10.1542/peds.109.1.12 [PMID: 11773535]
20. Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551-1559. doi:10.1016/S0140-6736(19)31344-3 [PMID: 31693715]
21. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000-1006. doi:10.1001/archophthalmol.2012.592 [PMID: 22491394]
22. Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133(4):391-397. doi:10.1001/jamaophthalmol.2014.5373 [PMID: 25590811]
23. Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143-149. doi:10.3928/23258160-20140306-08 [PMID: 24635157]
24. Trese MT. Surgical results of stage V retrolental fibroplasia and timing of surgical repair. Ophthalmology. 1984;91(5):461-466. doi:10.1016/s0161-6420(84)34269-2 [PMID: 6610843]
25. Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity. Br J Ophthalmol. 1996;80(5):425-428. doi:10.1136/bjo.80.5.425 [PMID: 8695565]
26. Tasman W, Brown GC, Schaffer DB, et al. Late complications of retinal detachment in premature infants. Ophthalmology. 1984;91(12):1611-1617. doi:10.1016/s0161-6420(84)34113-3 [PMID: 6084219]
27. Schmidt B, Roberts RS, Davis PG, et al. Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. Am J Respir Crit Care Med. 2015;192(2):174-180. doi:10.1164/rccm.201502-0318OC [PMID: 25932660]
28. Johansson S, Iliadou A, Bergvall N, Tuvemo T, Norman M, Cnattingius S. Risk of high blood pressure among young men increases with the degree of immaturity at birth. Circulation. 2005;112(22):3430-3436. doi:10.1161/CIRCULATIONAHA.105.540906 [PMID: 16301343]
29. Filippi L, Cavallaro G, Bagnoli P, et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570-1577.e6. doi:10.1016/j.jpeds.2013.07.049 [PMID: 24054431]
30. Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder AR. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med. 1998;338(22):1572-1576. doi:10.1056/NEJM199805283382202 [PMID: 9603794]
31. Brown JM, Campbell JP, Beers A, et al. Automated diagnosis of plus disease in retinopathy of prematurity using deep convolutional neural networks. JAMA Ophthalmol. 2018;136(7):803-810. doi:10.1001/jamaophthalmol.2018.1934 [PMID: 29801159]

Anti-VEGF Era and Treatment Advances

32. Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172(3):278-286. doi:10.1001/jamapediatrics.2017.4838 [PMID: 29379954]
33. Quinn GE, Ying GS, Daniel E, et al. Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol. 2014;132(10):1178-1184. doi:10.1001/jamaophthalmol.2014.1604 [PMID: 25010141]
34. Taylor S, Brown JM, Gupta K, et al. Monitoring disease progression with a quantitative severity scale for retinopathy of prematurity using deep learning. JAMA Ophthalmol. 2019;137(9):1022-1028. doi:10.1001/jamaophthalmol.2019.2433 [PMID: 31268466]

Global Screening and Third Epidemic

35. Vinekar A, Gilbert C, Dogra M, et al. The KIDROP model of combining strategies for providing retinopathy of prematurity screening in underserved areas in India using wide-field imaging, tele-medicine, non-physician graders and smart phone reporting. Indian J Ophthalmol. 2014;62(1):41-49. doi:10.4103/0301-4738.126178 [PMID: 24492500]
36. Wallace DK, Quinn GE, Freedman SF, Chiang MF. Agreement among pediatric ophthalmologists in diagnosing plus and pre-plus disease in retinopathy of prematurity. J AAPOS. 2008;12(4):352-356. doi:10.1016/j.jaapos.2007.11.022 [PMID: 18329925]
37. Hewing NJ, Kaufman DR, Chan RVP, Chiang MF. Plus disease in retinopathy of prematurity: qualitative analysis of diagnostic process by experts. JAMA Ophthalmol. 2013;131(8):1026-1032. doi:10.1001/jamaophthalmol.2013.305 [PMID: 23744899]
38. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-250. [PMID: 15747762]
39. Ortiz-Seller A, Tomas-Torrent E, Foulquie-Moreno E, et al. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. Surv Ophthalmol. 2024;69(3):399-412. doi:10.1016/j.survophthal.2024.01.004 [PMID: 38432359]
40. Chang YS, Chen YH, Lai TT, et al. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology. 2022;129(9):1023-1036. doi:10.1016/j.ophtha.2022.04.021 [PMID: 35842190]
41. Jalali S, Matalia J, Hussain A, Anand R. Modification of screening criteria for retinopathy of prematurity in India: an evidence-based approach. Am J Ophthalmol. 2006;141(5):966-968. doi:10.1016/j.ajo.2005.11.045 [PMID: 16678520]
42. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol. 2001;119(8):1110-1118. doi:10.1001/archopht.119.8.1110 [PMID: 11483076]
43. Bancalari A, Schade R, Pena R, Gonzalez C. Aggressive posterior retinopathy of prematurity: a comparison of the characteristics and outcomes of treated eyes to the BEAT-ROP trial. Ophthalmol Retina. 2020;4(10):1025-1030. doi:10.1016/j.oret.2020.04.017 [PMID: 32334035]
44. VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(5):619-633. doi:10.1016/j.ophtha.2016.12.025 [PMID: 28242105]
45. Patel SN, Happ HC, Vercio A, et al. Timing of treatment for retinopathy of prematurity: does treatment on the weekend affect outcomes? J Pediatr Ophthalmol Strabismus. 2019;56(2):105-109. doi:10.3928/01913913-20181211-01 [PMID: 30917182]
46. Ataer-Cansizoglu E, Bolon-Canedo V, Campbell JP, et al. Computer-based image analysis for plus disease diagnosis in retinopathy of prematurity: performance of the "i-ROP" system. Trans Am Ophthalmol Soc. 2015;113:T1. [PMID: 26330592]

Further Resources

• Bliss (UK Premature Baby Charity): ROP Information
• National Eye Institute (NIH): ROP Facts
• International ROP Action Group: ROP Global Resources

Additional References (47-51):

47. Di Fiore JM, Bloom JN, Orge F, et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr. 2010;157(1):69-73. doi:10.1016/j.jpeds.2010.01.046 [PMID: 20304417]

48. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009;21(2):182-187. doi:10.1097/MOP.0b013e32832925f1 [PMID: 19663040]

49. Redd TK, Campbell JP, Brown JM, et al. Evaluation of a deep learning image assessment system for detecting severe retinopathy of prematurity. Br J Ophthalmol. 2019;103(5):580-584. doi:10.1136/bjophthalmol-2018-313156 [PMID: 30150316]

50. Hellström A, Hård AL, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123(4):e638-e645. doi:10.1542/peds.2008-2697 [PMID: 19289449]

51. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327-333.e1. doi:10.1016/j.ajo.2011.07.005 [PMID: 21930258]

---

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.